News

  • PainReform Announces Closing of $20.0 Million Initial Public Offering

    10 September. 2020

    PainReform Ltd. (NASDAQ:PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the closing on September 3, 2020 of its initial public offering of 2,500,000 units at a price of $8.00 per unit. Each unit consisted of one Ordinary Share and one Warrant to purchase […]

    More...

  • PainReform Announces Pricing of $20.0 Million Initial Public Offering

    8 September. 2020

    ¬†PainReform Ltd. (NasdaqCM:PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the pricing of its initial public offering of 2,500,000 units at a price of $8.00 per unit. Each unit consists of one Ordinary Share and one Warrant to purchase one Ordinary Share. The […]

    More...

  • PainReform Gets FDA Approval for Phase III Post-Operative Pain Relief Study

    18 July. 2018  |  PRNewswire

    PainReform Ltd, developer of a proprietary reformulation technology, has received FDA approval to conduct two pivotal Phase III clinical trials for post-operative pain relief in soft and hard tissue.

    More...

  • PainReform to conduct Phase III trials for pain reliever

    19 June. 2018  |  Globes

    Israeli drug development company Painreform says it will conduct two Phase III trials of its pain reliever, based on delayed release over 72 hours. The new drug is designed for professional use in hospitals on patients recovering from surgery. Very few pain relievers reach the stage of Phase III trials, the final stage before marketing.

    More...